Kornimate/medical-research-clean huggingface dataset:
comparison of 2 hemostasis techniques after transradial coronary

Conditions: Coronary Artery Disease With Myocardial Infarction

Summary: randomized clinical trial to compare radial artery patency after transradial coronary catheterization using 2 different hemostasis techniques. patients submitted to diagnostic or therapeutic coronary catheterization will be prospectively enrolled in this single-center trial and will be randomized to radial hemostasis with terumoband® or a standardized compressive dressing with gauze and elastic bandage.

randomized clinical trial to compare radial artery patency after transradial coronary catheterization using 2 different hemostasis techniques. patients submitted to diagnostic or therapeutic coronary catheterization will be prospectively enrolled in this single-center trial and will be randomized to radial hemostasis with terumoband® or a standardized compressive dressing with gauze and elastic bandage. interventions: radial hemostasis with terumoband® and radial hemostasis with a standardized compressive dressing

Eligibility criteria:
inclusion criteria: * adult patients submitted to elective or urgent coronary catheterization who presented with a a, b or c curve on oximetry test before the procedure exclusion criteria: * inability to understand the study and sign the informed consent form
effect of dynamic cupping versus myofascial release therapy in patients with mechanical neck pain

Conditions: Mechanical Neck Pain

Summary: a quasi-experimental study will investigate the effect of dry cupping massage versus myofascial release on patients with mechanical neck pain.

purpose: to investigate the effect of dry cupping massage versus myofascial release on pain level, range of motion, and functional level in mechanical neck pain... background: neck pain is a multivariate disease and is a leading issue in a modernized society. the economic burden of neck pain is remarkable and includes treatment costs, reduced productivity, and job-related problems (cohen, 2015). there is no one definitive treatment for neck pain. however, different pharmacological and non-pharmacological treatments have been recommended, including laser therapy, massage, acupuncture, yoga, and aquatic therapy (corvillo et al., 2020). however, no studies are focusing on comparing the effect of dynamic cupping and myofascial release in mechanical neck pain. hypotheses: there will be a non-significant difference between dry cupping massage and myofascial release on pain level, range of motion, and functional level in patients with mechanical neck pain... research question: will there be a difference between dry cupping massage versus myofascial release on pain level, range of motion, and functional level in patients with mechanical neck pain?

Eligibility criteria:
inclusion criteria: 1. age between 18- 40 years. 2. participants have experienced mechanical neck pain for at least the previous 3 months. exclusion criteria: * participants aged below 18 years-old and those above 40 years old * mechanical neck pain due to trauma, disc protrusion, congenital deformity of the spine, spinal stenosis, and rheumatoid disease.
the role of systemic immuno-inflammatory factors in resectable pancreatic adenocarcinoma

Conditions: Pancreas Cancer, Duct Cell Adenocarcinoma

Summary: pancreatic cancer is a highly aggressive malignancy, its prognosis remaining poor despite the current advances in treatment. systemic inflammatory reaction has been recently recognized as an important factor in the progression of cancer. the immune-inflammatory response has been measured through different scores or ratios, that combine the values of circulating immune cells, like neutrophil-to-lymphocyte ratio (nlr), platelet-to-lymphocyte ratio (plr), lymphocyte-to-monocyte ratio (lmr), systemic immune-inflammation index (sii), prognostic nutritional index (pni). the utility of these scores in different types of cancer has been more and more discussed. in pancreatic cancer, there has been no definite conclusion regarding the role of systemic immune-inflammatory factors; since controversies still exist, a deeper exploration of this subject, through more studies is welcomed. our study intends to analyze the utility of systemic immune-inflammatory markers in resectable pancreatic cancer. our study is an observational cohort study, with retrospective data collection; it is a single-center study, that takes place in a hospital with experience in hepato-bilio-pancreatic surgery. the investigators intended to evaluate the role of the circulating immune cells (neutrophils, lymphocytes, monocytes) and different immune-inflammatory scores (nlr, lmr, plr, sii, pni) in predicting the overall survival of patients diagnosed with pancreatic ductal adenocarcinoma, that undergo curative surgical treatment. the investigators intended to assess the prognosis power of these factors in both preoperative and postoperative settings, as well as their dynamic after surgery. through this study, the investigators hope to identify easy-to determine and easy-to-use markers that can be incorporated in clinical practice and that can effectively predict survival in pancreatic cancer patients. nonetheless, the investigators want to explore the dynamic of the immune-inflammatory markers after curative surgery.


Eligibility criteria:
inclusion criteria: * diagnosis of pancreatic ductal adenocarcinoma * curative surgical procedure exclusion criteria: * other histopathological types of pancreatic malignancies * palliative surgical interventions * incomplete/ insufficient data
prevalence of molar incisor hypomineralization among a group of egyptian children from 8 to 12 years old in dakahlia

Conditions: Molar Incisor Hypomineralization

Summary: the aim of this study is to assess the prevalence of mih among a group of egyptian children aged from 8-12 years old in dakahlia governorate schools.

* clinical examination will be carried out in the school laboratory or an empty class, in day light, teeth will be cleaned gently using gauze and wet with saliva during examination. a disposable diagnostic set (mirror, probe) will be used for each patient where mirrors will be used for proper visualization especially for maxillary teeth. blunt explorers will be used to aid in tactile sensation if needed, as during the differentiation between rough and smooth enamel edges and/or during the inspection of the caries extent if it exists. no diagnostic radiographs will be taken. * an examination chart (appendix 1) will be filled for each child including: date, name, age, address, gender, school, medical health and any previous dental treatment, followed by clinical examination to the four first permanent molars and the eight maxillary and mandibular incisors to detect the presence of mih and its severity based on european academy of pediatric dentistry (eapd) criteria . to diagnose molar incisor hypomineralization, at least one affected first permanent molar is required. extracted first permanent molar will be recorded as affected if another first permanent molar has a defecting mih * each child affected with mih will be given a letter outlining his dental health status, to inform the parents and indicate the need for treatment. examination chart date: personal information: name: age: gender: address: school: medical history: dental history: clinical examination: 8 7 6 5 4 3 2 1 1 2 3 4 5 6 7 8 8 7 6 5 4 3 2 1 1 2 3 4 5 6 7 8 severity according to eapd: code description severity 0 no defect 1. white or creamy demarcated opacities/mild mild 2. yellow or brown demarcated opacities mild 3. a enamel loss moderate 3b enamel and dentin loss severe 3c atypical large cavities extended to pulp and covering one or more tubercle severe 4 atypical restorations severe 5 extracted tooth severe comments: mih: presence / absence severity: mild / moderate /severe (appendix 1)

Eligibility criteria:
inclusion criteria: * acceptance for participation in the study. * children aged from 8-12 years old. * eruption of at four first permanent molars. * both genders. exclusion criteria: * uncooperative children. * children with orthodontic appliances. * children with systemic diseases which may affect teeth development. * children suffering from any other type of enamel defect as enamel hypoplasia and amelogenesis imperfecta.

Keywords: molar incisor hypomineralization , enamel defects.
a study comparing halobetasol propionate and tazarotene topical lotion 0.01%/0.045% to duobrii® lotion (halobetasol propionate and tazarotene lotion), 0.01%/0.045% (reference listed drug) in the treatment of moderate to severe plaque psoriasis.

Conditions: Plaque Psoriasis

Summary: to evaluate the therapeutic equivalence and safety of halobetasol propionate and tazarotene topical lotion 0.01%/0.045% (taro pharmaceuticals u.s.a., inc.) and duobrii® lotion (halobetasol and tazarotene lotion), 0.01%/0.045% (reference listed drug) in the treatment of moderate to severe plaque psoriasis.

a multi-center, double-blind, randomized, placebo controlled, parallel-group study, comparing halobetasol propionate and tazarotene topical lotion 0.01%/0.045% (taro pharmaceuticals u.s.a., inc.) and duobrii® lotion (halobetasol propionate and tazarotene lotion), 0.01%/0.045% (reference listed drug) in the treatment of moderate to severe plaque psoriasis.

Eligibility criteria:
inclusion criteria: * healthy male or non-pregnant female aged ≥ 18 years * subjects must have provided irb approved written informed consent * subjects must be willing and able to understand and comply with the requirements of the protocol, including attendance at the required study visits * subjects with a clinical diagnosis of stable (at least 6 months) plaque psoriasis involving at least 3% and no more than 12% of the body surface area (bsa). affected areas should not include the axillae, face, scalp, soles, palms, and intertriginous areas exclusion criteria: * female subjects who are pregnant, nursing or planning to become pregnant during study participation. * females of childbearing potential who do not agree to utilize an adequate form of contraception. * subjects with a known hypersensitivity to tazarotene, halobetasol propionate, other corticosteroids, or to any ingredients in the study drugs. * subjects with current diagnosis of unstable forms of psoriasis including guttate, erythrodermic, exfoliative or pustular psoriasis.
effect of prone positioning in patients with covid-19

Conditions: Covid19

Summary: covid-19 is affecting the people around the world and the infected individuals' may either stay asymptomatic or present to hospitals with severe distress and life threatening symptoms. the objective of the study is to investigate role of prone positioning and alternate nostril breathing in patients with covid-19.

in this quasi experimental study, 30 patients aged 40-80 years of either gender with a confirmed diagnosis of covid-19 receiving supplemental oxygen were recruited from dhq hospital faisalabad. patients were grouped into two a \& b. we collected baseline data on demographics and anthropometrics. after baseline data collection, all the patients were helped into the prone position, which was maintained for a minimum duration of three hours. after that patients in group b performed alternate nostril breathing for 10 minutes with help of physiotherapist. clinical data were re-collected on 3rd day of intervention one hour after returning to the supine position in group a and after alternate nostril breathing in group b. the main study outcome was the variation in oxygenation (partial pressure of oxygen \[pao2\]/ fractional concentration of oxygen in inspired air \[fio2\]) between baseline and resupination, and general psychological state through gad-7 general anxiety disorder questionnaire.

Eligibility criteria:
inclusion criteria: age: 40-80 gender: both gcs score:15 exclusion criteria: * copd intubated ards smoker neurological disorder

Keywords: covid-19 general anxiety disorder-7 prone position alternate nostril breathing
results of arthroscopic massive rotator cuff tears repair with or without using long head of biceps tendon

Conditions: Rotator Cuff Tears

Summary: the goal of this clinical trial is to asses the function of arthroscopic repair with or without superior capsular augmentation using biceps tendon .

all patients included in this clinical trial will be informed by written consent will undergo a one week screening to determine the eligibility for study entry. patients who meet the eligibility requirements will be randomised in a single blinded manner ( patients).

Eligibility criteria:
inclusion criteria: * age 40 to 80 years old * patients with massive rotator cuff tear exclusion criteria: * patients with glenohumeral arthritis * acromioclavicular arthritis that requires distal clavicle resection * patients with other intra articular pathology like slap lesion * neural damage( brachial plexus injury) * revision cases

Keywords: massive cuff tears biceps autograft arthroscopic repair partial or complete retear superior capsular augmentation
novottf treatment signatures in glioblastoma patients at autopsy

Conditions: Glioblastoma

Summary: this study will assess whole brain samples from glioblastoma patients at autopsy to determine the underlying pathological signatures of tumor treatment fields at autopsy.

rationale: optune therapy with tumor treatment fields (ttfields) has recently been fda approved for the treatment of newly diagnosed glioblastoma due to a recent clinical trial that showed improvement in progression free survival and overall survival compared to standard therapy. (1) ttfields also have a role in the recurrent glioblastoma treatment where it has demonstrated equal efficacy to second-line chemotherapy also has been shown to tumor progression and improve overall survival.(2) though preclinical studies are ongoing, glioblastoma patients who have undergone ttfield therapy have not yet been assessed at autopsy to determine both the pathological signature of ttfield treatment, and the pattern of failure. this study will determine how the underlying pathological signatures of tumors treated with ttfields differ from those naïve to ttfields by comparing tumor tissue at autopsy. study: all patients undergoing ttfield therapy for newly diagnosed and recurrent glioblastoma will be considered for inclusion for this study. the investigators expect to enroll five patients per year for four years, totaling 10 patients treated upfront and 10 patients treated at tumor recurrence. an objective of this study is to determine differences in the pathological pattern of failure when patients are treated with ttfields at initial diagnosis (up-front) compared to those treated at tumor recurrence.

Eligibility criteria:
inclusion criteria: * newly diagnosed glioblastoma, world health organization (who) grade iv, patients undergoing ttfield therapy. * recurrent glioblastoma who grade iv, patients undergoing ttfield therapy. exclusion criteria: * ttfield compliance \< 75%. * any contraindication to optune ttfield treatment. * initial brain tumor diagnosis \< who grade iv. * duration of ttfield therapy \< 3 months.

Keywords: glioblastoma brain tumor autopsy autopsy optune therapy tumor treatment fields ttfields recurrent glioblastoma grade iv brain tumor newly diagnosed glioblastoma
postoperative folfox4 only versus folfox4 plus transhepatic arterial chemotherapy (tac) in the treatment unresectable liver metastasis of colorectal cancer

Conditions: Unresectable Liver Metastasis of Colorectal Cancer

Summary: the purpose of this study is to investigate whether tac plus folfox4 are able to improve resection rate and overall survival in patients receiving primary colorectal tumor resection than given folfox4 only.

we administered three cycles folfox4 plus on tac (oxaliplatin, fudr and mmc) or folfox4 only to primary colorectal tumor resected patients with unresected liver metastasis. the study endpoints were resection rate of liver metastasis, progression-free survival, overall survival as evaluated by intent-to-treat analysis.

Eligibility criteria:
inclusion criteria: * age \< 75 years with histologically proven adenocarcinoma of the colon or rectum * no severe major organ dysfunction * who performance status of 0 or 1 * no prior cancer therapy * with measurable unresectableliver metastasis * without other metastasis exclusion criteria: * age \>= 75 * severe major organ dysfunction * who performance status of \>1 * prior cancer therapy * with other metastasis

Keywords: liver metastasis colorectal cancer
a study of mk-4700 alone or with pembrolizumab in participants with advanced or metastatic solid tumors (mk-4700-001)

Conditions: Malignant Neoplasm

Summary: the goal of this study is to learn about the safety of different doses of mk-4700 and if people tolerate them. the study will also measure what happens in a person's body over time when mk-4700 is given alone or with pembrolizumab (mk-3475) in order to find a dose that is safe, tolerated, and may work to treat certain types of cancer.


Eligibility criteria:
inclusion criteria: the key inclusion criteria include but are not limited to the following: * has histologically or cytologically confirmed advanced/metastatic solid tumor by pathology report who have experienced disease progression on or after prior anti-cancer treatments, or been intolerant to, or refused all treatment known to confer clinical benefit * has head and neck squamous cell carcinoma (hnscc), melanoma (cutaneous), non-small cell lung cancer (nsclc), cervical cancer, triple negative breast cancer (tnbc), urothelial carcinoma (uc), or renal cell carcinoma (rcc; clear cell, papillary) * if human immunodeficiency virus (hiv) infected, must have well controlled hiv on antiretroviral therapy (art) * has normal cardiac function exclusion criteria: the key exclusion criteria include but are not limited to the following: * if hiv-infected with a history of kaposi's sarcoma and/or multicentric castleman's disease * has known additional malignancy that is progressing or has required active treatment within the past 2 years * has known active central nervous system (cns) metastases and/or carcinomatous meningitis * has active autoimmune disease that has required systemic treatment in the past 2 years except replacement therapy * has history of (noninfectious) pneumonitis/interstitial lung disease that required steroids * has current pneumonitis/interstitial lung disease * has active infection requiring systemic therapy * has known history of hepatitis b (defined as hepatitis b surface antigen reactive) or known active hepatitis c virus infection * has had an allogeneic tissue/solid organ transplant in the last 5 years

Keywords: head and neck squamous cell carcinoma melanoma non-small cell lung cancer cervical cancer triple negative breast cancer urothelial carcinoma renal cell carcinoma
expanded access for lorlatinib for patients with non small cell lung cancer alk positive or ros1 positive

Conditions: Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

Summary: this expanded access study has being designed following a demand from the fda, given the increase in the number of request for single patient inds for lorlatinib

given that an expanded access study does not meet the definition of a controlled clinical investigation, and as such, is not considered an applicable drug clinical trial per nih, basic results for such studies are not required to be reported. protocol b7461020 has been identified as an expanded access trial, and has been registered to clinicaltrials.gov, however basic results will not be posted. this statement has been placed in the detailed description section of the protocol registration on clinicaltrials.gov.

Eligibility criteria:
inclusion criteria: * ineligibility for participation in any ongoing clinical study of the investigational product * age ≥18 years * histologically or cytologically diagnosis of metastatic nsclc that carries an alk rearrangement or a ros1 rearrangement * for alk positive patients: failure to prior treatment with at least one alk-tki. if prior alk-tki was crizotinib, additional prior treatment required with at least one second generation alk-tki registered and commercially available. for patients with resistance mutations not covered by other inhibitors (eg, alk g1202r resistance mutation), prior treatment with an alk/ros1 inhibitor is not required. * for ros1 positive patients: failure to prior treatment with at least crizotinib * adequate bone marrow, liver, renal, pancreatic functions * negative pregnancy test at screening exclusion criteria: * previous surgery, chemotherapy, radiotherapy or other anti cancer therapy or participation in other studies with investigational drugs within the timeframe indicated in the protocol * history of interstitial fibrosis or interstitial lung disease * concomitant use of prohibited medication * clinically significant cardiovascular disease: cerebral vascular accident/stroke, myocardial infarction, unstable angina, congestive heart failure, second degree or third degree atrioventricular block (unless paced) or any av block with pr \>220 msec * ongoing cardiac dysrhythmias, uncontrolled atrial fibrillation,bradycardia, ecg with qtc \>470 msec, or congenital long qt syndrome * history of or predisposing characteristics for acute pancreatitis

Keywords: nsclc